Nan dat 12 mas 2022, NMPA (SFDA) te pibliye yon avi ki apwouve chanjman aplikasyon pou tès pwòp tèt ou nan pwodwi antijèn COVID-19 pa Nanjing Vazyme Biotech Co, Ltd, Beijing Jinwofu Bioengineering Technology Co, Ltd, Shenzhen Huada Yinyuan Pharmaceutical. Teknoloji co, Ltd, Guangzhou Wondfo B...
Li plis